Patent ID: 6489295
Filing Date: 2002-12-03
Classification: A61K,A61P,C07K,G01N,Y02A

Abstract:
A method of reducing hyperplasia or inducing hypoplasia of small bowel tissue in a subject comprising delivering to said subject a therapeutically effective amount of a mammalian GLP-2 analog having GLP-2 antagonist activity, wherein said analog is mutated relative to a mammalian GLP-2 such that(i) from one to four of the first four N-terminal residue of said mammalian GLP-2 are deleted, or (ii) at least one amino acid selected from the amino acid positions corresponding to human GLP-2 at Asp15, Phe22, Thr29, Thr32 and Asp33 is substituted with an amino acid which does not naturally occur at that position in the mammalian GLP-2, or (iii) position Ala2 is substituted with an amino acid selected from the group consisting of Leu, Cys, Glu, Arg, Trp, and PO3-Tyr, or (iv) two or more substitutions or deletions as defined in (i), (ii) and (iii) are combined; wherein delivery of said mammalian GLP-2 analog results in the reduction of hyperplasia or induction of hypoplasia in small bowel tissue of said subject.